-
Mashup Score: 17Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial - 6 month(s) ago
BACKGROUND: Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about
Source: www.ahajournals.orgCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 12Dapagliflozin in Patients with Heart Failure and Deterioration in Estimated Glomerular Filtration Rate to - 8 month(s) ago
STRUCTURED ABSTRACT Background SGLT-2 inhibitors are guideline-recommended in the management of heart failure(HF). While these therapies can be initiated even in patients with comorbid CKD, some pa…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
#ESCCongress #JACC LBCT SimPub: New from #DAPA-HF & #DELIVER: Benefit-to-risk ratio may favor continuation of #SGLT2i dapagliflozin in #HeartFailure pts w/ deterioration in kidney function to eGFR<25ml/min/1.73m2 https://t.co/3EF3ILm9fR @safchat @mvaduganathan @scottsolomon https://t.co/AdhogqJ4Ik
-
-
Mashup Score: 7
This secondary analysis of a randomized clinical trial evaluates the association between treatment with dapagliflozin vs placebo and improvement in components of the Kansas City Cardiomyopathy Questionnaire.
Source: jamanetwork.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
This analysis examined the effect of #dapagliflozin on the 23 individual components of the #KCCQ in #DELIVER. https://t.co/hbdrJ62UrQ @PeikertA @AlvinChandraMD @mvaduganathan @scottdsolomon #HeartFailure2023
-
-
Mashup Score: 0Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - 11 month(s) ago
AbstractAims. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
News from DELIVER trial: dapagliflozin's safety and efficacy across a wide range of background diuretic use! #dapaglifozin #DELIVER #heart failure #LVEF #safety #efficacy @ESC_Journals @escardio https://t.co/lyS4L8jMtB https://t.co/NOsgeIwPdS
-
-
Mashup Score: 4Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - 11 month(s) ago
AbstractAims. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
🔥 #DELIVER 🍀#Dapa ⬇️ 32% new initiation of loop-diuretics in #HFmrEF & #HFpEF ❤️🔥 #Dapa reduced the mean dose of loop-douretic when compared to placebo 👌 Not bad as diuretic effect 🚀 @gcfmd @nephondemand @gbiondizoccai @JavedButler1 @mvaduganathan https://t.co/2TkXu1Y1Cn https://t.co/LzDypqyeb3
-
-
Mashup Score: 5Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial - 11 month(s) ago
AbstractAims. Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced o
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#DELIVER Diuretics presented by @safchat to close her exceptional performance at #HeartFailure2023, simultaneous publication in @escardio #EHJ Important learnings to guide implementation of #SGLT2i in HF! https://t.co/Gsdg8Yzorh https://t.co/EhBkSvUvnz
-
-
Mashup Score: 20Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER - 11 month(s) ago
AbstractAims. Because an increased risk of amputation with canagliflozin was reported in the CANVAS trials, there has been a concern about the safety of sodium–
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
#DAPAHF #DELIVER Peripheral Artery Disease brilliantly presented by @JawadHButt at #HeartFailure2023 LBCT & simultaneously published in @escardio #EHJ https://t.co/F8J0j51lRj Editorial “Good for your heart and safe for your toes” https://t.co/E1bGXOYudQ https://t.co/6qtW0FggTd
-
-
Mashup Score: 7
This secondary analysis of a randomized clinical trial evaluates the association between treatment with dapagliflozin vs placebo and improvement in components of the Kansas City Cardiomyopathy Questionnaire.
Source: jamanetwork.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
This analysis examined the effect of #dapagliflozin on the 23 individual components of the #KCCQ in #DELIVER. https://t.co/pOS8dYECrE @PeikertA @AlvinChandraMD @mvaduganathan @scottdsolomon #HeartFailure2023 https://t.co/aZ9fgAXEsT
-
-
Mashup Score: 7Farxiga extended in the US to reduce risk of cardiovascular death and hospitalisation for heart failure to a broader range of patients - 12 month(s) ago
FDA approval means patients with heart failure can benefit from Farxiga regardless of left ventricular ejection fraction status AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval by the Food and Drug Administration (FDA)…
Source: www.astrazeneca.comCategories: Cardiologists, Latest HeadlinesTweet-
.@US_FDA expands approval of #SGLT2i dapagliflozin to reduce CV death, HF hosp, & urgent HF visits to all adults w HF regardless of #LVEF based on #DELIVER. A 2nd major approval for #LVEF >40%. 👏🏾 to vision & leadership by @scottdsolomon @UoGHeartFailure https://t.co/lMoyi0PujH https://t.co/OqZ0yf9DOQ
-
-
Mashup Score: 2
In patients with heart failure with mildly reduced or preserved ejection fraction, oral dapagliflozin improved heart failure outcomes to a similar extent in three glycaemia subgroups: normoglycaemia, prediabetes, and type 2 diabetes. Moreover, the heart failure benefits of dapagliflozin seem to be consistent across a continuous glycaemic range.
Categories: Endocrinology, Latest HeadlinesTweet-
Efficacy & safety of #dapagliflozin in patients with #HeartFailure with mildly reduced or preserved ejection fraction by baseline #glycaemic status (#DELIVER): a subgroup analysis from an international, randomised, placebo-controlled trial https://t.co/YDLCsqzYbU #diabetes #T2D
-
New from #DELIVER in @CircAHA by @BrighamFellows #JohnOstrominski Dapagliflozin and Apparent Treatment-Resistant Hypertension in HF 🔑 Resistant HTN identified in >1 in 10 pts 🔑 SGLT2i consistently ↓ CV events 🔑 SGLT2i modestly ↓ SBP by ≈1-3 mmHg https://t.co/awY7WSUQ07 https://t.co/ZCOVnQaYij